Drugs for Neglected Diseases initiative:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Drugs for Neglected Diseases initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9283
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (HAT, or sleeping sickness), leishmaniasis, and Chagas disease, and conducts research and development projects for other neglected diseases including malaria, paediatric HIV, mycetoma, hepatitis C, and filarial infections. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. It also offers research programs for various organizations. It collaborates with private biotechnology companies, public institutions, academia and NGOs. The organization operates in Switzerland, the US, Kenya, India, Brazil, Malaysia and Japan. DNDi is headquartered in Geneva, Switzerland.

Drugs for Neglected Diseases initiative – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Takeda Pharma Enters into Agreement with DNDi 11
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12
Optibrium Enters into Partnership with Imperial College London and DNDi 13
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14
Institut Pasteur Korea Enters into Research Agreement with DNDi 15
DNDi Enters into Agreement with Takeda Pharma 16
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17
Celgene Global Health Expands Research Agreement DNDi 18
Institut Pasteur Korea and DNDi Enter into Research Agreement 19
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23
Drugs for Neglected Diseases initiative – Key Employees 24
Drugs for Neglected Diseases initiative – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Nov 08, 2017: DNDi/GARDP opens new South Africa liaison office, hosted by South African Medical Research Council 27
Corporate Communications 28
Aug 08, 2017: DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years 28
Government and Public Interest 29
Sep 12, 2018: New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier 29
Apr 13, 2018: Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa 30
Feb 06, 2018: New open source drug discovery project aims to develop mycetoma treatment 31
Other Significant Developments 32
Jan 18, 2018: Epichem Awarded One Year Contract Extension from DNDi 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Key Facts 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Deals By Therapy Area, 2012 to YTD 2018 8
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Takeda Pharma Enters into Agreement with DNDi 11
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 12
Optibrium Enters into Partnership with Imperial College London and DNDi 13
Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 14
Institut Pasteur Korea Enters into Research Agreement with DNDi 15
DNDi Enters into Agreement with Takeda Pharma 16
Bayer HealthCare Enters into Co-Development Agreement with Drugs for Neglected Diseases Initiative 17
Celgene Global Health Expands Research Agreement DNDi 18
Institut Pasteur Korea and DNDi Enter into Research Agreement 19
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 20
Astellas Pharma Enters Into Co-Development Agreement With DNDi For Neglected Diseases 21
Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 22
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 23
Drugs for Neglected Diseases initiative, Key Employees 24
Drugs for Neglected Diseases initiative, Other Locations 26

List of Figures
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Drugs for Neglected Diseases initiative, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Drugs for Neglected Diseases initiative:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Goodwin Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Goodwin Biotechnology Inc (GBI), a subsidiary of Wallace Pharmaceuticals Pvt Ltd is a healthcare company that develops and manufactures vaccines, monoclonal antibodies, recombinant proteins and bioconjugates. The company offers cell culture, purification, bioconjugation, biosimilars, aseptic …
  • TransMontaigne Product Services LLC:企業の戦略・SWOT・財務情報
    TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report Summary TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Blue Apron Inc. (APRN):企業の財務・戦略的SWOT分析
    Blue Apron Inc. (APRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sutter Health-製薬・医療分野:企業M&A・提携分析
    Summary Sutter Health (Sutter Health) is a non-profit healthcare service provider, which provides health care service through its hospitals, ambulatory surgery centers, cardiac centers, cancer centers, rehabilitation centers and others. It serves communities across Northern California- in the San Fr …
  • Agthia Group PJSC:企業の戦略・SWOT・財務情報
    Agthia Group PJSC - Strategy, SWOT and Corporate Finance Report Summary Agthia Group PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • FMR LLC:企業の戦略的SWOT分析
    FMR LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Sodra Skogsagarna ekonomisk forening:企業の戦略的SWOT分析
    Sodra Skogsagarna ekonomisk forening - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Laboratory Corporation of America Holdings:企業の戦略・SWOT・財務分析
    Laboratory Corporation of America Holdings - Strategy, SWOT and Corporate Finance Report Summary Laboratory Corporation of America Holdings - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • ConAgra Foods Inc:戦略・SWOT・企業財務分析
    ConAgra Foods Inc - Strategy, SWOT and Corporate Finance Report Summary ConAgra Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Lumenis Ltd:企業の戦略的SWOT分析
    Lumenis Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kot Addu Power Co Ltd:発電所・企業SWOT分析
    Kot Addu Power Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employe …
  • Tessi S.A. (TES):企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Redbiotec AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Redbiotec AG (Redbiotec) is a biopharmaceutical company that develops prophylactic vaccines, which target various virus associated diseases. The company produces multi component virus like particles and other protein assemblies through its rePAX coexpression technology. It is developing prod …
  • FortisAlberta Inc.:企業の戦略的SWOT分析
    FortisAlberta Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Arsenal Holdings plc:企業の戦略的SWOT分析
    Arsenal Holdings plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Alta Mesa Resources Inc:企業の戦略的SWOT分析
    Alta Mesa Resources Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Wave 80 Biosciences Inc:企業の製品パイプライン分析2018
    Summary Wave 80 Biosciences Inc (Wave 80) is a medical device company that develops molecular diagnostic instruments and consumables. The company develops molecular diagnostics instruments for chlamydia, respiratory illness, cancers, autoimmune diseases, hepatitis B, hepatitis C, HIV/AIDS and other …
  • The Trendlines Group Ltd (42T):製薬・医療:M&Aディール及び事業提携情報
    Summary The Trendlines Group Ltd (Trendlines) is a commercialization company that invents, discovers, invests, and incubates medical and agricultural technologies. The company offers business incubation, partner and channel development, market strategies, business plans, research and development and …
  • Bharat Dynamics Limited:企業の戦略・SWOT・財務情報
    Bharat Dynamics Limited - Strategy, SWOT and Corporate Finance Report Summary Bharat Dynamics Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ricardo plc:企業の戦略・SWOT・財務情報
    Ricardo plc - Strategy, SWOT and Corporate Finance Report Summary Ricardo plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆